Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.46 |
| ▸ | RHEB | Q15382 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1507211 | 0.92 | KDM4E (0.49) | SMN1; SMN2MAPTMAPK1PKMGAA | |
| SCHEMBL22533987 | 0.87 | SMN1; SMN2 (0.55) | SMN1; SMN2MAPTMAPK1PKMGAA | |
| SCHEMBL6093891 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2MAPTMAPK1PKMGAA | |
| SCHEMBL3737238 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTMAPK1PKMGAA | |
| SCHEMBL8906504 | 0.85 | L3MBTL1 (0.54) | SMN1; SMN2MAPTMAPK1PKMGAA | |
| SCHEMBL15294555 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTMAPK1PKMGAA | |
| SCHEMBL4244735 | 0.84 | MAPT (0.52) | SMN1; SMN2MAPTMAPK1PKMGAA | |
| SCHEMBL7485743 | 0.83 | F10 (0.52) | SMN1; SMN2MAPTMAPK1PKMGAA | |
| SCHEMBL8632161 | 0.83 | MAPT (0.55) | SMN1; SMN2MAPTMAPK1PKMGAA | |
| SCHEMBL23280103 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTMAPK1PKMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300485-B1 | PYRROLO-[2, 3-C]-PYRIDINE DERIVATIVES AS P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME (US) | 2012-01-18 | — | — | EP | disclosed |
| US-8017605-B2 | P38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017605-B2 | P38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20110105430-A1 | PYRROLO [2,3-C] PYRIDINE DERIVATIVES AS P38 KINEASE INHIBITING AGENTS | SAHOO SOUMYA P | 2011-05-05 | — | — | US | disclosed |
| US-20110105430-A1 | PYRROLO [2,3-C] PYRIDINE DERIVATIVES AS P38 KINEASE INHIBITING AGENTS | SAHOO SOUMYA P | 2011-05-05 | — | — | US | disclosed |
| US-20090325953-A1 | P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME LLC | 2009-12-31 | — | — | US | disclosed |
| US-20090325953-A1 | P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME LLC | 2009-12-31 | — | — | US | disclosed |
| WO-2009152072-A1 | PYRROLO [2, 3-C] PYRIDINE DERIVATIVES AS P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-02-19 | — | — | US | disclosed |
| EP-1993536-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20070249599-A1 | Novel Chemical Compounds | DUFFY KEVIN J | 2007-10-25 | — | — | US | disclosed |
| WO-2007103755-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249599-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | SMN1; SMN2 2249/4885MAPT 1769/4885MAPK1 1623/4885 |
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | PIK3CA, BTK, PI4KA | SMN1; SMN2 2523/4885MAPT 2228/4885MAPK1 1490/4885 |
| US-20090325953-A1 | P38 KINASE INHIBITING AGENTS | MAPK1, MAPK8, MAPKAPK2 | SMN1; SMN2 3365/4885MAPT 60/4885MAPK1 1/4885 |
| US-20110105430-A1 | PYRROLO [2,3-C] PYRIDINE DERIVATIVES AS P38 KINEASE INHIBITING AGENTS | MAPK1, MAP3K8, MAPK8 | SMN1; SMN2 3521/4885MAPT 383/4885MAPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.